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A plethora of candidate genes have been identified
for complex polygenic disorders, but the underlying
disease mechanisms remain largely unknown. We
explored the pathophysiology of type 2 diabetes
(T2D) by analyzing global gene expression in human
pancreatic islets. A group of coexpressed genes
(module), enriched for interleukin-1-related genes,
was associated with T2D and reduced insulin secre-
tion. One of the module genes that was highly over-
expressed in islets from T2D patients is SFRP4,
which encodes secreted frizzled-related protein 4.
SFRP4 expression correlated with inflammatory
markers, and its release from islets was stimulated
by interleukin-1b. Elevated systemic SFRP4 caused
reduced glucose tolerance through decreased islet
expression of Ca2+ channels and suppressed insulin
exocytosis. SFRP4 thus provides a link between islet
inflammation and impaired insulin secretion. More-
over, the protein was increased in serum from T2D
patients several years before the diagnosis, suggest-
ing that SFRP4 could be a potential biomarker for
islet dysfunction in T2D.
INTRODUCTION
Large-scale gene expression data hold great promise to provide
pathophysiological insights for a range of diseases, but there are
several limitations with our current way of analyzing such
information (Lander, 2011; Rosengren et al., 2010; Saxena
et al., 2007; Schadt, 2009; Sladek et al., 2007; Voight et al.,
2010; Zeggini et al., 2008). Network models, in which genes
are represented as nodes and their connections as edges,
have been proposed as a useful framework for studying complexCell Mbiological data (Barabasi and Albert, 1999; Baraba´si et al., 2011;
Ravasz et al., 2002; Schadt, 2009; Taneera et al., 2012). To take
full advantage of those models, it is essential to analyze disease-
relevant tissues and to combine bioinformatics with mecha-
nistic validations. Using type 2 diabetes (T2D) as an example
of a complex polygenic disorder, we have explored whether co-
expression networks in human pancreatic islets could be used to
identify disease genes.
RESULTS
Gene Coexpression Analysis Identifies a Module that
Is Associated with T2D, Elevated HbA1c, and Reduced
Insulin Secretion
Impaired insulin secretion is a cardinal feature of T2D, typically
combined with insulin resistance, but the underlying mecha-
nisms are largely unknown. We obtained global microarray
expression data from islets from 48 human donors, of which 10
had T2D (see Table S1 available online), and investigated the
gene expression topology with the weighted gene coexpression
network analysis framework developed by Zhang and Horvath
(Zhang and Horvath, 2005) (see the Supplemental Experimental
Procedures). The connectivity, reflecting coexpression, was cal-
culated for all pairs of gene expression traits. The resulting
coexpression network exhibited the characteristic scale-free
properties (R2 > 0.9; Table S2) of biological networks (Ravasz
et al., 2002). Next, the topological overlap, as a measure of rela-
tive gene interconnectedness, was computed and used to iden-
tify 17 gene modules (Figure 1A).
Rather than analyzing each gene expression trait individually,
the first principal component of the gene expression traits of
each module (the ‘‘module eigengene’’) was used. We identified
an eigengene representing a module with 174 genes (Table S3),
which had higher values in islets from diabetic donors (p = 0.010;
Table S4) and was correlated with HbA1c, reflecting long-term
blood glucose (p = 0.010 in all donors; n.s. when analyzing
only nondiabetic [ND] donors) and reduced glucose-stimulatedetabolism 16, 625–633, November 7, 2012 ª2012 Elsevier Inc. 625
Figure 1. Topological Characteristics and Association between Gene Expression and T2D Traits
(A) Symmetrically arranged heatmap of the topological overlap matrix for which the rows and columns are sorted by the hierarchical clustering tree used to define
modules. Intensity from light yellow (low) to red (high) denotes the topological overlap between genes. The red circle indicates the T2D-associated module.
(B–D) For each of the 174 genes in the T2D module, the absolute value of the correlation of the gene expression trait and diabetes status (B), HbA1c (C), or
glucose-stimulated insulin secretion (D) is displayed against the logarithm of kin for the gene. Red dots indicate SFRP4. p and r values for the correlation between
kin and gene expression association with the diabetes traits were calculated by Spearman’s rank correlation.
(E) SFRP4 expression (log2-transformed) in human islets from nondiabetic (n = 38) and diabetic (n = 10) donors. p value was calculated using logistic regression.
(F) SFRP4 expression in human islets plotted against HbA1c in the donors (n = 38).
(G) SFRP4 expression plotted versus insulin secretion at 16.7 mM glucose in human islets (n = 35). p values in (F) and (G) were calculated using linear regression
and are given for all donors as well as only nondiabetic (ND) donors, for which n = 28 in (F) and n = 26 in (G).
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SFRP4 Is Overexpressed in Type 2 Diabetesinsulin secretion (p = 0.0047 in all donors; n.s. in ND). The corre-
sponding module was enriched for interleukin-1 (IL-1)-binding
genes (43.3-fold enrichment; p = 0.026) and IL-1 receptor activity
(61.8-fold enrichment; p = 0.0079) as well as RNA-processing
genes. No other module eigengene was significantly associated
with T2D (Table S4; p values are nominal without correction for
multiple testing).
We explored the possibility of using topological information to
prioritize genes in the T2D-associatedmodule. The total connec-
tivity of a gene (the degree k) is a central parameter, as scale-free
networks are characterized by a few high-degree hubs, which
connect a large number of peripheral nodes (Albert et al.,
2000; Carter et al., 2004; Ravasz et al., 2002).
For each gene in the T2D module, we analyzed the con-
nectivity within (kin) and outside (kout) the module (Zhang and
Horvath, 2005). There was a significant correlation between kin,
but not kout, and gene expression association with diabetes
status (Figures 1B–1D). We therefore selected the most con-
nected genes in the module for further analyses. Of these, the
expression of SFRP4, ASAM, and FBLN1was most highly asso-
ciated with T2D. IL18R1, IL1RL1, and SFRP4 correlated most626 Cell Metabolism 16, 625–633, November 7, 2012 ª2012 Elsevierstrongly with HbA1c andSFRP4, IL18R1, andABCE1with insulin
secretion. SFRP4 was among the top three hub genes associ-
ated with all T2D traits (Figures 1E–1G).
The network analysis was replicated in another data set using
human islet microarrays from 29 donors, 10 of which had T2D
(Table S5). The coexpression network generated from these
data also exhibited scale-free properties (R2 > 0.8; Table S6),
and 20 gene modules were identified (Table S7). Statistical
power was lower in this smaller data set, and no module eigen-
gene was significantly associated with T2D. However, an eigen-
gene representing a module with 123 genes (Table S8) was
nominally associated with HbA1c (p = 0.034, all 29 donors) and
showed a tendency for higher values in diabetic donors (p =
0.072). Interestingly, the module contains SFRP4, as well as
a high degree of shared genes with the T2D-associated module
identified in the 48 donors initially analyzed (p = 1.9E-11 using
Fisher’s exact test), including IL-1 receptors (85.9-fold enrich-
ment). There was an association between kin and gene ex-
pression association with diabetes status (p = 0.0003) also in
the replication set, and SFRP4 was among the most highly con-
nected genes in the module.Inc.
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SFRP4 Is Overexpressed in Type 2 DiabetesSFRP4 encodes secreted frizzled-related protein 4, which is
a 40 kDa protein with an N-terminal cysteine-rich domain with
sequence similarity with frizzled (Fz) receptors and a C-terminal
netrin-like domain that has been suggested to interact with
extracellular matrix proteins (Bovolenta et al., 2008; Rattner
et al., 1997). SFRP4 is an extracellular regulator of the Wingless
(Wnt) pathway. Interestingly, several T2D-associated genetic
variants locate to genes in the Wnt pathway (Saxena et al.,
2007; Sladek et al., 2007; Voight et al., 2010; Zeggini
et al., 2008), including the Wnt effector TCF7L2 (da Silva Xavier
et al., 2009; Grant et al., 2006). SFRP4 is involved in tissue devel-
opment and cancer, as well as phosphate metabolism (Berndt
et al., 2003; Bovolenta et al., 2008; Heller et al., 2002), but to
date it has not been implicated in T2D.
SFRP4 Reduces Insulin Secretion through Decreased
Ca2+ Influx and Insulin Exocytosis in Pancreatic b Cells
We studied the effect of SFRP4 on insulin secretion by exposing
isolated mouse pancreatic islets to recombinant SFRP4 for
24 hr followed by 1 hr stimulation with 16.7 mM glucose. The
peptide dose-dependently reduced glucose-stimulated insulin
secretion with maximal inhibition observed at 30 nM (Figures
2A and S1A); insulin content or b cell viability were not affected
(Figures S1B–S1D). A comparable inhibitory effect of 24 hr treat-
ment with SFRP4 on glucose-stimulated insulin secretion was
also observed in human islets (Figure 2B). SFRP4 did not affect
basal insulin secretion (measured at 2.8 mM glucose) in mouse
(Figure 2A) or human islets (Figure 2B), and there was no asso-
ciation between basal insulin release and SFRP4 expression
(p = 0.2). In both human and mouse islets, insulin secretion
was unaffected by acute exposure to SFRP4 (Figures S1E
and S1F).
Pancreatic b cells release insulin through Ca2+-dependent
exocytosis, which can be monitored as increases in cell capac-
itance (Rorsman and Renstro¨m, 2003). Pretreatment with
SFRP4 decreased the exocytotic responses to a train of ten
depolarizations (applied to simulate glucose-induced electrical
activity) in both human (Figure 2C) and mouse b cells (Fig-
ure S1G) relative to nontreated control cells. This was paralleled
by a reduction of the integrated Ca2+ current (that reports the
cumulative Ca2+ entry) (Figures 2D and S1H). However, there
was no change in the Ca2+ sensitivity of the exocytotic process
(defined as the capacitance increase divided by the integrated
Ca2+ current; Figure S1I), which suggests that the exocytosis
machinery was intact. Conversely, siRNA-mediated silencing
of SFRP4 in dispersed mouse b cells (63% ± 2% mRNA knock-
down; n = 3) increased Ca2+ influx by 65% and exocytosis by
42% (Figure 2E) and was paralleled by a 30% reduction of accu-
mulated SFRP4 secreted into the medium following transfec-
tion. The siRNA treatment had no effect on insulin secretion
from intact mouse islets (Figure S1J), putatively due to poor
transfection efficiency in the islet core, which confounds the
whole-islet experiments. To specifically study the effects of
SFRP4 originating from b cells, we silenced SFRP4 in the clonal
b cell line INS832/13 (76% ± 6% mRNA knockdown), which
enhanced glucose-stimulated insulin release by 25% (p =
0.029, one-tailed; Figures S1K and S1L).
Next, electrical activity was assessed using current-clamp
recordings of mouse islet cell clusters treated with or withoutCell MSFRP4. The electrical activity consisted of depolarized plateaux
on which action potentials were superimposed, interrupted by
periods of repolarization. There was a tendency for lower action
potential amplitude and frequency in SFRP4-treated cell clus-
ters compared with control cells (Figure S2), while the plateau
potential did not differ between the conditions (43 ± 1 mV
without and 42 ± 1 mV with SFRP4). To specifically study the
effect of SFRP4 on glucose-induced changes in intracellular
Ca2+ ([Ca2+]i) we conducted ratiometric measurements with
Fura-2. These experiments showed that the peak increase in
[Ca2+]i elicited by an elevation of glucose from 2.8 to 16.7 mM
was reduced by 65% in islets treated with SFRP4 for 24 hr
(p = 0.025; Figures 2F and 2G). Furthermore, SFRP4-treated
islets exhibited reduced insulin secretion both in response
to 200 mM tolbutamide (which closes the ATP-sensitive K+
channels [KATP channels]) and high (50 mM) K
+ (leading to
membrane depolarization) (Figure 2A). Taken together, the
data suggest that SFRP4 inhibits insulin secretion at a step distal
to KATP channel closure and cell depolarization through sup-
pressed Ca2+ influx.
SFRP4 Affects Wnt Signaling and L-Type and P/Q-Type
Ca2+ Channels
SFRP4 has variably been reported to activate or inhibit Wnt
signaling in different tissues (Carmon and Loose, 2008; Feng
et al., 2009; Gelebart et al., 2008; Lee et al., 2008; Park et al.,
2008; Suzuki et al., 2004). The Wnt pathway is activated via
Gi/o-coupled frizzled receptors (Liu et al., 2001), and inhibition
of Gi/o proteins by pertussis toxin abolished SFRP4-mediated
suppression of insulin secretion (Figure 3A). Furthermore, the
ratio of unphosphorylated versus total b-catenin was elevated
in SFRP4-treated mouse islets, suggestive of canonical Wnt
activation (Figure 3B). Unphosphorylated b-catenin translocates
to the nucleus where it affects TCF/LEF transcription factors,
including TCF7L2 (Grant et al., 2006). SFRP4 increased TCF/LEF
activity (Figure 3C), confirming the stimulatory effect on Wnt
signaling. Noncanonical Wnt pathways were unaffected (Figures
S3A–S3E). SFRP4 inhibition of b cell exocytosis was not influ-
enced by cotreatment with canonical (Carmon and Loose,
2008) or noncanonical Wnt proteins (Ma and Wang, 2007)
(Figure S3F).
TCF/LEF activation has been shown to repress Ca2+ channel
expression (Wisniewska et al., 2010), and we investigated
whether SFRP4-induced suppression of insulin release in-
volved altered expression of Ca2+ channels. Notably, both
L-type (CaV1.2 and CaV1.3) and P/Q-type (CaV2.1) Ca
2+ chan-
nels were downregulated by SFRP4 in human b cells (Fig-
ure S4A). T-type Ca2+ channels (CaV3.2) were unaffected. We
next analyzed the effect of the L-type Ca2+ channel blocker
isradipine and the P/Q-type blocker u-agatoxin IVA (Braun
et al., 2008) on the current-voltage (I-V) relationship in human
b cells incubated with or without SFRP4 for 24 hr. SFRP4-treated
cells displayed a pronounced reduction of the peak current
(55% at 0 mV; p = 3.5E-5; Figure 3D). Interestingly, while
isradipine suppressed the current in control cells (p = 0.028 at
0 mV), it was without effect in SFRP4-treated b cells (Figure 3E).
Likewise, u-agatoxin IVA decreased the peak current in control
cells (p = 0.001 at 0 mV), but was largely ineffective in SFRP4-
treated b cells, except for a tendency (p = 0.3) for a suppressionetabolism 16, 625–633, November 7, 2012 ª2012 Elsevier Inc. 627
Figure 2. Effects of SFRP4 on Insulin Secretion and b Cell Exocytosis
(A) Insulin secretion in response to 1 hr incubations with 2.8 mM glucose, 16.7 mM glucose, 2.8 mM glucose plus 50 mM K+, or 8.3 mM glucose plus 200 mM
tolbutamide in mouse islets that were cultured with or without 30 nM SFRP4 for 24 hr prior to experiments. SFRP4 was not present during the 1 hr incubations.
Data are from 6–12 experiments per group. p values are from unpaired comparisons.
(B) Insulin secretion in response to 1 hr incubations with 2.8 or 16.7 mM glucose in human islets cultured in the absence or presence of 30 nM SFRP4 for 24 hr.
Data are from 5–8 experiments per group from each of three donors at 2.8 mM glucose, and data from 4–12 experiments per group from each of 17 donors at
16.7 mM glucose. p values are from paired comparisons for each donor.
(C) Increase in cell capacitance (DC), reflecting exocytosis, evoked by a train of ten 500ms depolarizations from70 to 0mV applied to a human b cell to simulate
glucose-induced electrical activity. Histogram shows total capacitance increase (SDC) in human b cells preincubated without or with 30 nM SFRP4 for 24 hr.
SFRP4 was not present in the extracellular solution during the recordings. Data are from 3–11 experiments per donor from 16 donors with paired comparisons.
(D) The Ca2+ current (I) in response to the first depolarization of the train. The bars denote the integrated Ca2+ current (charge) in human b cells preincubated
without or with SFRP4. Data are from same cells as in (C).
(E) Left histogram shows average total capacitance increase in response to a train stimulus in mouse b cells treated with control siRNA or siRNA against SFRP4.
Right bars show the mean integrated Ca2+ current (charge) in response to the first depolarization. Data are from 17 and 39 cells, respectively. p values are from
unpaired one-sided tests.
(F) Representative recordings of Fura-2 fluorescence at 340 versus 380 nm (DF340/F380 from the average baseline) in mouse islets that had been incubated
for 24 hr in the absence or presence of 30 nM SFRP4. The extracellular glucose concentration was changed from 2.8 to 16.7 mM during the experiment as
indicated. Sampling rate is 0.2 Hz.
(G) The histogram shows the mean DF340/F380 peak at high glucose in control (n = 5) and SFRP4-treated islets (n = 5). Data are mean ± SEM. *p < 0.05; **p < 0.01;
***p < 0.001.
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Figure 3. Regulation of SFRP4 and Effects in b Cells
(A) Insulin secretion in response to 16.7 mM glucose in mouse islets pretreated with or without 100 ng/ml pertussis toxin (PTX) or 30 nMSFRP4 as indicated (n = 6
per group).
(B) Immunoblots of total protein frommouse islets incubated for 24 hr in the absence or presence of SFRP4. Polyclonal antisera against actin, total b-catenin, and
unphosphorylated b-catenin were used as indicated. The histogram shows average levels of unphosphorylated versus total b-catenin (n = 6 blots).
(C) Activity of an inducible TCF/LEF-responsive reporter in INS832/13 cells incubated with or without SFRP4. Data are from three experiments with five wells per
experiment and group.
(D) Current-voltage relationship for the total Ca2+ current in the absence or presence of 2 mM isradipine or 200 nM u-agatoxin IVA in control or SFRP4-treated
human b cells (n = 3–15 cells per group).
(E) L- and P/Q-type Ca2+ currents obtained by subtracting currents recorded in the presence of isradipine or u-agatoxin IVA from currents observed in the
absence of the respective antagonist. The cells were preincubated without or with 30 nM SFRP4 for 24 hr.
(F) Immunostaining of human b cell with anti-insulin (red) and anti-SFRP4 (blue) antibodies. Lower right shows overlay. Scale bars, 2 mm.
(G) Human islet mRNA expression of indicated genes. Islets were incubated with or without 25 ng/ml IL-1b or 30 nM SFRP4 as shown (n = 8 donors).
(H) SFRP4 content in 2 ml medium with 100 islets incubated with or without 25 ng/ml IL-1b for 24 hr (n = 4 experiments). Data are mean ± SEM. *p < 0.05;
**p < 0.01; ***p < 0.001.
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SFRP4 Is Overexpressed in Type 2 Diabetesat 0 mV (25% compared with the 55% reduction in control
cells). These findings suggest that both L-type and P/Q-type
Ca2+ channels are suppressed by SFRP4. Indeed, the expres-Cell Msion of SFRP4 in human islets was negatively correlated with
CACNA1A (CaV2.1) (p = 0.008; r = 0.376) and CACNA1D
(CaV1.3) mRNA (p = 0.003; r = 0.426).etabolism 16, 625–633, November 7, 2012 ª2012 Elsevier Inc. 629
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SFRP4 Is Overexpressed in Type 2 DiabetesSFRP4 Expression and Release Are Stimulated by
Interleukin-1b
The regulation of SFRP4 production and release has not been
characterized. Immunohistochemistry demonstrated SFRP4 in
both a and b cells without preferential accumulation in the
secretory granules (Figures 3F and S4B). Stimulation for 1 hr
with 16.7 mM glucose or 50 mM K+ to elicit depolarization-
induced exocytosis did not affect SFRP4 release, indicating
that SFRP4 is released in a constitutive fashion rather than cose-
creted with insulin (Figures S4C and S4D).
There was no significant association between known T2D
gene variants and SFRP4 expression (Table S9). Since the T2D
module containing SFRP4 was enriched for IL-1-related genes,
we hypothesized that SFRP4 might be an inflammatory medi-
ator. Interestingly, human islets incubated with IL-1b displayed
a 1.8-fold elevation of SFRP4 mRNA (Figure 3G) and a 3-fold
higher secretion of the protein into the medium (Figure 3H).
Moreover, 24 hr treatment of human islets with 100 mM
YVAD-CMK, an inhibitor of IL-1b convertase that cleaves and
activates the IL-1b precursor (Samad et al., 2001), or recom-
binant human IL-1 receptor antagonist (500 ng/ml) reduced
SFRP4 secretion (Figures S4E and S4F). SFRP4 expression
correlated with islet content of IL-6 (p = 5E-5; r = 0.58) and IL-8
(p = 0.001; r = 0.52). By contrast, IL-1b, IL-6, and IL-8 expres-
sion was not affected by SFRP4 exposure (Figures 3G, S4G,
and S4H), which suggests that SFRP4 acts downstream of
IL-1b to reduce insulin secretion. Indeed, analysis of tran-
scription factor binding sites near SFRP4 (see Supplemental
Experimental Procedures) demonstrated several putative
binding sites for NF-kB, which is elevated by IL-1b (Figure 3G).
Moreover, the inhibitory effect of IL-1b on insulin secretion was
attenuated (p = 0.001) in INS832/13 cells transfected with siRNA
against SFRP4 compared with cells treated with an inactive
control siRNA (Figure S4I). Due to incomplete SFRP4 knock-
down (76% ± 6%) it is, however, difficult to estimate the exact
extent by which SFRP4 contributes to the IL-1b effect.
SFRP4 Injections In Vivo Reduce Insulin Secretion in
Mice, and SFRP4 Is Elevated in Serum fromT2DPatients
Next, mice were injected three times over 24 hr with SFRP4,
which resulted in glucose intolerance and reduced insulin
secretion (Figure 4A). Interestingly, isolated islets from SFRP4-
treated mice displayed decreased glucose-induced insulin
secretion as well as suppressed b cell Ca2+ influx and exocytosis
(Figures 4B and 4C). This demonstrates that elevated SFRP4
in vivo induces sustained inhibitory effects on b cell function.
Finally, we investigated SFRP4 concentration in serum from
88 individuals (Groop et al., 1996) who were analyzed at three
different visits (median interval 3 years) (Table S10). Serum
levels of SFRP4 were significantly elevated in T2D patients
(p = 0.018, age-, sex- and BMI-corrected; n = 23) compared
with ND subjects (n = 51) (Figure 4D). Interestingly, ND in-
dividuals who later developed T2D (‘‘converters’’; n = 14) had
significantly higher SFRP4 already at the initial visits and
prior to presentation of the disease (p = 0.046) (Figure 4E).
Among ND individuals with SFRP4 levels below the median
(23.7 ng/ml), 9% (3 out of 35 subjects) developed T2D at a later
stage, while 37% (11 out of 30) of those with SFRP4 above the
median developed the disease (Table S11). The odds ratio (OR)630 Cell Metabolism 16, 625–633, November 7, 2012 ª2012 Elsevierwas 5.35 (95% CI: 1.29–22.2; p = 0.021, age-, sex- and BMI-
corrected).
These analyses were replicated in an extended cohort with 69
converters and 69 matched controls, in which serum SFRP4
was analyzed and an oral glucose tolerance test (OGTT) con-
ducted at two consecutive visits (median interval 4 years [range
1–15 years]) (Table S12). The converters had been classified as
ND at the first visit but were diagnosed with T2D at the second
visit. In ND individuals, SFRP4 was associated with higher
fasting glucose (p = 0.004; beta = 0.142), reduced insulin sensi-
tivity index (p = 0.002; beta = 0.176), and lower disposition
index (insulin secretion adjusted for insulin sensitivity; p =
0.029; beta = 0.186; Table S13). Serum concentration was
not affected by BMI, sex, patient age, or sample age (Table
S13). Supporting the results from the initial analysis, SFRP4
was significantly elevated in T2D individuals by the time of diag-
nosis (the second visit) compared with controls (39% increase;
one-tailed p = 0.044 and beta = 0.164 with age, sex, and BMI
correction; Figure 4F). Interestingly, and further corroborating
the initial findings, converters had increased SFRP4 already at
their first visit, prior to clinical diagnosis (37% increase com-
pared with controls; one-tailed p = 0.034 and beta = 0.163
with correction for age, sex, and BMI). The p values were
0.12 and 0.07 (one-tailed), respectively, if adjusting for fasting
glucose and glucose at 2 hr during the OGTT, which suggests
that the effect is largely driven by the association between
SFRP4 and glucose levels. We next studied the usefulness of
categorizing individuals into quartiles based on serum SFRP4
at the first visit. As shown in Figures 4G and 4H, individuals
with SFRP4 in the upper quartile were at particular risk of
developing T2D (p = 0.005; OR 3.32 [95% CI: 1.34–8.24])
compared with subjects in quartiles 1–3. The risk elevation
was significant even after correction for fasting glucose (p =
0.018; OR = 2.89 [95% CI: 1.07–7.85]) or glucose at 2 hr during
the OGTT (p = 0.022; OR = 3.05 [95% CI: 1.04–9.0]). Further
study is needed to assess if SFRP4 can be used as a biomarker
for T2D risk independent of glucose.
DISCUSSION
The study identifies SFRP4 as a molecular link between islet
inflammation and defective insulin secretion. It also demon-
strates the utility of modular analyses of biological data to find
disease genes that are not obvious candidates from genetic
association studies, although it is difficult to establish causality
from expression studies with a restricted number of subjects.
SFRP4 affects Wnt signaling, which influences a wide scope
of genes, here reflected by the suppression of two different
voltage-gated Ca2+ channels that in turn lead to reduced insulin
exocytosis. Indeed, the main effect of SFRP4 in b cells was the
reduction of insulin secretion stimulated by glucose and other
secretagogues, while insulin content and b cell viability were
unaltered. It is of interest that the Wnt pathway has recently
been implicated in the pathogenesis of T2D from the identifica-
tion of several T2D-associated DNA variants that locate near
genes in the Wnt pathway (Saxena et al., 2007; Sladek et al.,
2007; Voight et al., 2010; Zeggini et al., 2008), most notably
the Wnt effector TCF7L2 (da Silva Xavier et al., 2009; Grant
et al., 2006).Inc.
Figure 4. In Vivo Effects of SFRP4 and
SFRP4 in Human Serum
(A) Glucose and insulin levels during an intrave-
nous glucose tolerance test (IVGTT). PBS or
SFRP4 (200 mg/kg) were injected 24, 16, and 8 hr
before the IVGTT. Data are from 12 control and 13
SFRP4-treated mice.
(B) Insulin secretion in vitro in response to a 1 hr
incubation at 16.7 mM glucose from islets isolated
from PBS- or SFRP4-injected mice. Data are
from eight (PBS) and ten (SFRP4) experiments,
respectively.
(C) Increase in cell capacitance (DC) evoked by
a depolarization train in b cells from mice injected
with PBS or SFRP4. The histograms show the
average total capacitance increase (SDC) and
integrated Ca2+ current (charge). Data are from 13
and 16 cells from control and SFRP4-treatedmice,
respectively. Islets were not exposed to SFRP4
after isolation from the animals for experiments in
(B) and (C).
(D) Serum concentration of SFRP4 in individuals
who remained nondiabetic at all visits (ND; n = 51
individuals) and subjects with T2D at all visits (T2D;
n = 23 individuals).
(E) Serum SFRP4 measured at visit 1 and 2 in
nondiabetic individuals who later developed T2D
(converters; n = 14 individuals) compared with
subjects who remained nondiabetic (ND; p value
from one-sided comparisons corrected for age,
sex, and BMI).
(F) Serum SFRP4 measured in individuals who
were nondiabetic at both visit 1 (n = 61) and 2
(n = 64) and converters who were nondiabetic at
visit 1 (n = 62) and diagnosed with T2D at visit 2
(n = 60).
(G) Study subjects were categorized into quartiles
based on serum SFRP4 at visit 1, and the histo-
gram shows the number of nondiabetic individuals
and converters, respectively, in different quartiles.
N = 30, 31, 31, and 31 individuals in each quartile.
(H) Kaplan-Meier plot that shows the cumulative
increase of individuals diagnosed with T2D over
a period of up to 15 years in different quartiles
of serum SFRP4 at visit 1. Data are mean ± SEM.
*p < 0.05; **p < 0.01.
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SFRP4 Is Overexpressed in Type 2 DiabetesOur data demonstrate that SFRP4 is present in both a and
b cells and is released from islets, probably in a constitutive
fashion. The gene coexpression module containing SFRP4 was
enriched for IL-1-related genes, and we found that the expres-
sion and release of SFRP4 from islets was stimulated by IL-1b.
Interestingly, analysis of b cell-enriched areas of pancreatic
sections by laser-capture microdissection has shown that
several inflammatory genes that are induced by IL-1b are over-
expressed in T2D (Igoillo-Esteve et al., 2010). Moreover, IL-1b
antagonism improves glycemia and b cell function (Cavelti-
Weder et al., 2012; Dinarello et al., 2010; Larsen et al., 2007).
The present data explain previous observations that IL-1b
inhibits glucose-stimulated Ca2+-uptake and insulin release by
a pertussis toxin-sensitive mechanism (Helqvist et al., 1989;
Rabuazzo et al., 1995; Thaik et al., 1995). Since SFRP4 is asso-
ciated with several inflammatory mediators in human islets itCell Mcannot be excluded that other cytokines in addition to IL-1b
also affect SFRP4 release.
Secreted frizzled-related proteins (SFRPs) have a C-terminal
netrin-like domain, which binds heparin and heparan sulfate
proteoglycans in the extracellular matrix and facilitates the
accumulation of SFRPs at high local concentrations at the site
of secretion (Bafico et al., 1999; Salic et al., 1997; Uren et al.,
2000). This makes it likely that the intraislet concentration of
SFRP4 is considerably higher than that in serum, and our
measurements of the amount of SFRP4 released from islets
(1 pg/islet over 24 hr; Figure S4F) clearly suggest that the
concentration used in the experiments (30 nM) is in the physio-
logical range.
SFRP4 in serum was associated with elevated fasting glucose
and reduced disposition index. However, it was also associated
with impaired insulin sensitivity, indicating that the protein couldetabolism 16, 625–633, November 7, 2012 ª2012 Elsevier Inc. 631
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SFRP4 Is Overexpressed in Type 2 Diabeteshave a plethora of metabolic effects and might be released from
several tissues involved in glucose homeostasis. It is interesting
to note from the siRNA experiments targeting SFRP4 that rela-
tively modest changes in the levels of released SFRP4 (30%
reduction using siRNA in mouse islets) can cause pronounced
alterations of islet function. The elevation of SFRP4 in serum
several years before the diagnosis highlights the protein as
a potential biomarker for the low-grade islet inflammation that
is commonly seen in T2D, and it might prove useful for early
disease detection in combination with glucose and other
biomarkers. Finally, our data raise the exciting possibility that
SFRP4 could be a therapeutic target for specific treatment of
islet dysfunction.
EXPERIMENTAL PROCEDURES
Human Islets
Experimental procedures were approved by the local ethical com-
mittees. Donated human pancreatic islets were obtained (with research
consent) from the Nordic Network for Clinical Islet Transplantations (Pro-
fessor O. Korsgren). Donors with known T2D or HbA1c > 6.0% and no
GAD antibodies were defined as having T2D. There was no difference in
islet purity between ND and T2D donors. See Tables S1 and S5 for data on
donors.
Insulin Secretion and Exocytosis Measurements
Insulin secretion from isolated islets and b cell exocytosis were measured as
previously described (Rosengren et al., 2010).
Pancreatic Islet Cell Viability
Islet cell viability was measured using an Aqueous One Solution Cell Prolifer-
ation Assay Reagent (Promega, Sweden) according to the manufacturer’s
instructions.
RNA Interference
Islets or cell lines were transfected with siRNAs using Lipofectamine RNAiMax
(Invitrogen, Sweden) and 45 nM oligonucleotides.
TCF/LEF Activity
TCF/LEF activity in INS832/13 cells was measured with the Wnt Cignal
Reporter Assay Kit (SABiosciences) according to the manufacturer’s
instructions.
[Ca2+]i Measurements
[Ca2+]i was estimated by Fura-2 and dual-wavelength fluorimetry.
SFRP4 Content
SFRP4 in serum and islet incubation medium was measured with a human
SFRP4 ELISA kit (Nordic Diagnostica, Sweden) according to the manufac-
turer’s instructions.
Quantitative PCR
RNA was extracted with chloroform precipitation using the mRNeasy Kit
(QIAGEN). Gene expression was measured by qPCR using TaqMan (Applied
Biosystems).
In Vivo Experiments
Female NMRI mice (30 g) were injected intraperitoneally with SFRP4
(200 mg/kg in PBS) or PBS at 24, 16, and 8 hr before intravenous glucose
tolerance tests (IVGTT). IVGTT was performed after 4 hr fasting.
Individuals from the Botnia Study
Serum samples were obtained from individuals (88 in the initial anal-
ysis and 138 in the replication) participating in the Botnia Study (Groop
et al., 1996). Individuals between 18 and 70 years were invited to prospective
visits.632 Cell Metabolism 16, 625–633, November 7, 2012 ª2012 ElsevierStatistical Analyses
Student’s t test was used for comparisons of data from the cellular and animal
experiments. For experiments using islets or b cells from human donors, the
average for each donor under the different conditions was used in the analyses
and compared with paired Student’s t test. One-sided tests were used for the
replication analyses, and two-sided tests were used otherwise.
The SFRP4 concentration in serum showed non-Gaussian distribu-
tion. Gaussian distribution was obtained using logarithm transformation. All
statistical analyses of serum SFRP4 were therefore performed using ln-
transformed data. All statistical analyses were performed using IBM SPSS
Statistics (ver 20.0).
ACCESSION NUMBERS
All human islet microarray data are MIAME compliant, and the raw data have
been deposited in a MIAME database (GEO, accession number: GSE41762).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, 13 tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2012.10.009.
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